Viral cross-class serpin inhibits vascular inflammation and T lymphocyte fratricide; a study in rodent models in vivo and human cell lines in vitro.

Poxviruses express highly active inhibitors, including serine proteinase inhibitors (serpins), designed to target host immune defense pathways. Recent work has demonstrated clinical efficacy for a secreted, myxomaviral serpin, Serp-1, which targets the thrombotic and thrombolytic proteases, suggesti...

Full description

Bibliographic Details
Main Authors: Kasinath Viswanathan, Ilze Bot, Liying Liu, Erbin Dai, Peter C Turner, Babajide Togonu-Bickersteth, Jakob Richardson, Jennifer A Davids, Jennifer M Williams, Mee Y Bartee, Hao Chen, Theo J C van Berkel, Erik A L Biessen, Richard W Moyer, Alexandra R Lucas
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3458838?pdf=render
_version_ 1819106091056758784
author Kasinath Viswanathan
Ilze Bot
Liying Liu
Erbin Dai
Peter C Turner
Babajide Togonu-Bickersteth
Jakob Richardson
Jennifer A Davids
Jennifer M Williams
Mee Y Bartee
Hao Chen
Theo J C van Berkel
Erik A L Biessen
Richard W Moyer
Alexandra R Lucas
author_facet Kasinath Viswanathan
Ilze Bot
Liying Liu
Erbin Dai
Peter C Turner
Babajide Togonu-Bickersteth
Jakob Richardson
Jennifer A Davids
Jennifer M Williams
Mee Y Bartee
Hao Chen
Theo J C van Berkel
Erik A L Biessen
Richard W Moyer
Alexandra R Lucas
author_sort Kasinath Viswanathan
collection DOAJ
description Poxviruses express highly active inhibitors, including serine proteinase inhibitors (serpins), designed to target host immune defense pathways. Recent work has demonstrated clinical efficacy for a secreted, myxomaviral serpin, Serp-1, which targets the thrombotic and thrombolytic proteases, suggesting that other viral serpins may have therapeutic application. Serp-2 and CrmA are intracellular cross-class poxviral serpins, with entirely distinct functions from the Serp-1 protein. Serp-2 and CrmA block the serine protease granzyme B (GzmB) and cysteine proteases, caspases 1 and 8, in apoptotic pathways, but have not been examined for extracellular anti-inflammatory activity. We examined the ability of these cross-class serpins to inhibit plaque growth after arterial damage or transplant and to reduce leukocyte apoptosis. We observed that purified Serp-2, but not CrmA, given as a systemic infusion after angioplasty, transplant, or cuff-compression injury markedly reduced plaque growth in mouse and rat models in vivo. Plaque growth was inhibited both locally at sites of surgical trauma, angioplasty or transplant, and systemically at non-injured sites in ApoE-deficient hyperlipidemic mice. With analysis in vitro of human cells in culture, Serp-2 selectively inhibited T cell caspase activity and blocked cytotoxic T cell (CTL) mediated killing of T lymphocytes (termed fratricide). Conversely, both Serp-2 and CrmA inhibited monocyte apoptosis. Serp-2 inhibitory activity was significantly compromised either in vitro with GzmB antibody or in vivo in ApoE/GzmB double knockout mice. Conclusions The viral cross-class serpin, Serp-2, that targets both apoptotic and inflammatory pathways, reduces vascular inflammation in a GzmB-dependent fashion in vivo, and inhibits human T cell apoptosis in vitro. These findings indicate that therapies targeting Granzyme B and/or T cell apoptosis may be used to inhibit T lymphocyte apoptosis and inflammation in response to arterial injury.
first_indexed 2024-12-22T02:32:37Z
format Article
id doaj.art-a5c6acf97d6f48ee9d839410654d30f7
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-22T02:32:37Z
publishDate 2012-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-a5c6acf97d6f48ee9d839410654d30f72022-12-21T18:41:51ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-0179e4469410.1371/journal.pone.0044694Viral cross-class serpin inhibits vascular inflammation and T lymphocyte fratricide; a study in rodent models in vivo and human cell lines in vitro.Kasinath ViswanathanIlze BotLiying LiuErbin DaiPeter C TurnerBabajide Togonu-BickerstethJakob RichardsonJennifer A DavidsJennifer M WilliamsMee Y BarteeHao ChenTheo J C van BerkelErik A L BiessenRichard W MoyerAlexandra R LucasPoxviruses express highly active inhibitors, including serine proteinase inhibitors (serpins), designed to target host immune defense pathways. Recent work has demonstrated clinical efficacy for a secreted, myxomaviral serpin, Serp-1, which targets the thrombotic and thrombolytic proteases, suggesting that other viral serpins may have therapeutic application. Serp-2 and CrmA are intracellular cross-class poxviral serpins, with entirely distinct functions from the Serp-1 protein. Serp-2 and CrmA block the serine protease granzyme B (GzmB) and cysteine proteases, caspases 1 and 8, in apoptotic pathways, but have not been examined for extracellular anti-inflammatory activity. We examined the ability of these cross-class serpins to inhibit plaque growth after arterial damage or transplant and to reduce leukocyte apoptosis. We observed that purified Serp-2, but not CrmA, given as a systemic infusion after angioplasty, transplant, or cuff-compression injury markedly reduced plaque growth in mouse and rat models in vivo. Plaque growth was inhibited both locally at sites of surgical trauma, angioplasty or transplant, and systemically at non-injured sites in ApoE-deficient hyperlipidemic mice. With analysis in vitro of human cells in culture, Serp-2 selectively inhibited T cell caspase activity and blocked cytotoxic T cell (CTL) mediated killing of T lymphocytes (termed fratricide). Conversely, both Serp-2 and CrmA inhibited monocyte apoptosis. Serp-2 inhibitory activity was significantly compromised either in vitro with GzmB antibody or in vivo in ApoE/GzmB double knockout mice. Conclusions The viral cross-class serpin, Serp-2, that targets both apoptotic and inflammatory pathways, reduces vascular inflammation in a GzmB-dependent fashion in vivo, and inhibits human T cell apoptosis in vitro. These findings indicate that therapies targeting Granzyme B and/or T cell apoptosis may be used to inhibit T lymphocyte apoptosis and inflammation in response to arterial injury.http://europepmc.org/articles/PMC3458838?pdf=render
spellingShingle Kasinath Viswanathan
Ilze Bot
Liying Liu
Erbin Dai
Peter C Turner
Babajide Togonu-Bickersteth
Jakob Richardson
Jennifer A Davids
Jennifer M Williams
Mee Y Bartee
Hao Chen
Theo J C van Berkel
Erik A L Biessen
Richard W Moyer
Alexandra R Lucas
Viral cross-class serpin inhibits vascular inflammation and T lymphocyte fratricide; a study in rodent models in vivo and human cell lines in vitro.
PLoS ONE
title Viral cross-class serpin inhibits vascular inflammation and T lymphocyte fratricide; a study in rodent models in vivo and human cell lines in vitro.
title_full Viral cross-class serpin inhibits vascular inflammation and T lymphocyte fratricide; a study in rodent models in vivo and human cell lines in vitro.
title_fullStr Viral cross-class serpin inhibits vascular inflammation and T lymphocyte fratricide; a study in rodent models in vivo and human cell lines in vitro.
title_full_unstemmed Viral cross-class serpin inhibits vascular inflammation and T lymphocyte fratricide; a study in rodent models in vivo and human cell lines in vitro.
title_short Viral cross-class serpin inhibits vascular inflammation and T lymphocyte fratricide; a study in rodent models in vivo and human cell lines in vitro.
title_sort viral cross class serpin inhibits vascular inflammation and t lymphocyte fratricide a study in rodent models in vivo and human cell lines in vitro
url http://europepmc.org/articles/PMC3458838?pdf=render
work_keys_str_mv AT kasinathviswanathan viralcrossclassserpininhibitsvascularinflammationandtlymphocytefratricideastudyinrodentmodelsinvivoandhumancelllinesinvitro
AT ilzebot viralcrossclassserpininhibitsvascularinflammationandtlymphocytefratricideastudyinrodentmodelsinvivoandhumancelllinesinvitro
AT liyingliu viralcrossclassserpininhibitsvascularinflammationandtlymphocytefratricideastudyinrodentmodelsinvivoandhumancelllinesinvitro
AT erbindai viralcrossclassserpininhibitsvascularinflammationandtlymphocytefratricideastudyinrodentmodelsinvivoandhumancelllinesinvitro
AT petercturner viralcrossclassserpininhibitsvascularinflammationandtlymphocytefratricideastudyinrodentmodelsinvivoandhumancelllinesinvitro
AT babajidetogonubickersteth viralcrossclassserpininhibitsvascularinflammationandtlymphocytefratricideastudyinrodentmodelsinvivoandhumancelllinesinvitro
AT jakobrichardson viralcrossclassserpininhibitsvascularinflammationandtlymphocytefratricideastudyinrodentmodelsinvivoandhumancelllinesinvitro
AT jenniferadavids viralcrossclassserpininhibitsvascularinflammationandtlymphocytefratricideastudyinrodentmodelsinvivoandhumancelllinesinvitro
AT jennifermwilliams viralcrossclassserpininhibitsvascularinflammationandtlymphocytefratricideastudyinrodentmodelsinvivoandhumancelllinesinvitro
AT meeybartee viralcrossclassserpininhibitsvascularinflammationandtlymphocytefratricideastudyinrodentmodelsinvivoandhumancelllinesinvitro
AT haochen viralcrossclassserpininhibitsvascularinflammationandtlymphocytefratricideastudyinrodentmodelsinvivoandhumancelllinesinvitro
AT theojcvanberkel viralcrossclassserpininhibitsvascularinflammationandtlymphocytefratricideastudyinrodentmodelsinvivoandhumancelllinesinvitro
AT erikalbiessen viralcrossclassserpininhibitsvascularinflammationandtlymphocytefratricideastudyinrodentmodelsinvivoandhumancelllinesinvitro
AT richardwmoyer viralcrossclassserpininhibitsvascularinflammationandtlymphocytefratricideastudyinrodentmodelsinvivoandhumancelllinesinvitro
AT alexandrarlucas viralcrossclassserpininhibitsvascularinflammationandtlymphocytefratricideastudyinrodentmodelsinvivoandhumancelllinesinvitro